Sobi is an international specialty healthcare company dedicated to rare diseases. Our mission is to develop and deliver innovative therapies and services to improve the lives of patients.

 Sobi has been involved
in the development and
manufacturing of
recombinant protein drugs
since the technology was first
developed more than
30 years ago.

 We want to make a difference
to people with rare diseases.

By working closely
with patients and their relatives
we learn about their daily
challenges and needs.


Sobi has a diversified and growth-oriented commercial product portfolio within three business lines.
To products

Our pipeline

Sobi’s pipeline programs are focused on recombinant protein drugs for specialist indications for the global market.
Read more about Sobi's pipeline

Annual General Meeting 2015

The Annual General Meeting in Swedish Orphan Biovitrum AB (publ), Reg. No. 556038-9321, will be held on Wednesday, May 6, 2015 at 4.00 p.m. at Näringslivets Hus, Storgatan 19, Stockholm, Sweden
Read more

Presentation of Sobi's Annual Report 2014

15 April, 2015 Sobi's Annual Report was published - Revenues for the full year totalled SEK 2,607 M (2,177), an increase of 20 per cent.

Share Price


Volume: 1,042,038
Ticker: SOBI
SSE Large